Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

124

Figures (1-1)

Tables (1-5)

Sum=173

Publishing Process of This Article

Item

Count

Browse

Download

Sum=53

Jan 15, 2025 (publication date) through Dec 23, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Oncol. Jan 15, 2025; 17(1): 96822
Published online Jan 15, 2025. doi: 10.4251/wjgo.v17.i1.96822

Table 3 Correlation between DPYD polymorphisms and toxicity

Parameter	Cohort A, n = 149	Cohort B, n = 151	P value
Patients with any AEs ≥ G3	39 (26.17)	67 (44.37)	0.00098
Patients with FP dose reduction	33 (22.15)	69 (45.7)	0.00002
Patients with ChT delay for any grade AEs	38 (25.5)	52 (34.44)	0.09136
Patients with hematological AEs ≥ G3	26 (17.4)	29 (19.3)	0.6944
Patients with non-hematological AEs ≥ G3	5 (3.4)	20 (13.3)	0.0028

Data are n (%). AEs: Adverse events; ChT: Chemotherapy; FP: Fluoropyrimidine.

Citation: D'Amato M, Iengo G, Massa N, Carlomagno C. Dihydropyrimidine dehydrogenase polymorphisms in patients with gastrointestinal malignancies and their impact on fluoropyrimidine tolerability: Experience from a single Italian institution. World J Gastrointest Oncol 2025; 17(1): 96822
URL: https://www.wjgnet.com/1948-5204/full/v17/i1/96822.htm
DOI: https://dx.doi.org/10.4251/wjgo.v17.i1.96822